Complete Response Letter from FDA for VersaFilm for Migraine- IntelGenx
IntelGenx Corp., a Canadian drug delivery company focusing on oral drug delivery, and RedHill Biopharma Ltd. , an Israeli biopharmaceutical company focused on the development and acquisition of late clinical-stage drugs, announced that they received a Complete Response Letter from the FDA regarding the New Drug Application ("NDA") for their VersaFilm Oral Film Product for the treatment of acute Migraines.
The questions raised by the FDA in the CRL regarding the NDA for the anti-migraine VersaFilm product primarily relate to third party Chemistry, Manufacturing and Controls and to the packaging and labeling of the product. No questions or deficiencies were raised relating to the product's safety and the FDA's CRL does not require additional clinical studies.
The rizatriptan film demonstrated bioequivalence in a successful pivotal clinical trial compared to the reference listed drug Maxalt MLT. IntelGenx submitted a 505(b)(2) New Drug Application for regulatory approval to the FDA in Q1 2013.
In addition to pursuing marketing approval in the U.S., and following a positive meeting with the German pharmaceuticals regulation authority BfArM in October 2013, IntelGenx and RedHill plan to complete the development program for the European market and submit a Marketing Authorization Application for marketing approval of the product in Europe later this year, with Germany as the reference member state under the European Mutual Recognition Procedure.
Related news and insights
Genentech/Roche announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet, or neovascular, age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections.
Oncopeptides announced that the company has decided to withdraw Pepaxto (INN melphalan flufenamide) from the market in the US, following the phase III OCEAN study, which showed an overall survival in the ITT population with a HR of 1.104. The decision has been made after interactions and dialogue with the FDA. Pepaxto was granted accelerated approval on February 26th 2021.
Johnson & Johnson announced the FDA has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine.